Quadrant Private Wealth Management LLC Lowers Holdings in Pfizer Inc. (NYSE:PFE)

Quadrant Private Wealth Management LLC lowered its holdings in Pfizer Inc. (NYSE:PFE) by 12.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 118,072 shares of the biopharmaceutical company’s stock after selling 17,099 shares during the quarter. Quadrant Private Wealth Management LLC’s holdings in Pfizer were worth $3,132,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Blue Trust Inc. increased its position in Pfizer by 133.4% during the fourth quarter. Blue Trust Inc. now owns 125,023 shares of the biopharmaceutical company’s stock valued at $3,317,000 after acquiring an additional 71,464 shares during the last quarter. Roman Butler Fullerton & Co. increased its position in Pfizer by 15.5% during the fourth quarter. Roman Butler Fullerton & Co. now owns 39,811 shares of the biopharmaceutical company’s stock valued at $1,069,000 after acquiring an additional 5,348 shares during the last quarter. Autumn Glory Partners LLC increased its position in Pfizer by 29.5% during the fourth quarter. Autumn Glory Partners LLC now owns 39,159 shares of the biopharmaceutical company’s stock valued at $1,045,000 after acquiring an additional 8,909 shares during the last quarter. AustralianSuper Pty Ltd purchased a new stake in Pfizer during the fourth quarter valued at $8,382,000. Finally, Asset Planning Inc bought a new stake in Pfizer during the fourth quarter valued at about $754,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of a number of analyst reports. UBS Group reduced their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Bank of America reiterated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Citigroup cut their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Guggenheim reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by insiders.

Pfizer Trading Down 0.6 %

Shares of NYSE:PFE opened at $25.50 on Friday. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The business’s fifty day simple moving average is $26.28 and its 200-day simple moving average is $27.62. The company has a market capitalization of $144.48 billion, a PE ratio of 18.08, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the previous year, the business earned $0.10 EPS. The firm’s revenue for the quarter was up 24.7% on a year-over-year basis. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.75%. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.